Myriad Genetics Inc (MYGN): Shareholders' Equity

Annual figures by period end, from SEC filings.

$368.00M
As of 2025-12-31
$303.90M
As of 2026-06-30
-25.4%
3-year compound annual growth
-16.0%
5-year compound annual growth
$1.09B2009-06-30: $434.22M2010-06-30: $557.58M2011-06-30: $566.79M2012-06-30: $635.66M2013-06-30: $728.60M2014-06-30: $719.00M2015-06-30: $661.70M2016-06-30: $739.60M2017-06-30: $768.40M2018-06-30: $966.10M2019-06-30: $1.09B2020-06-30: $918.20M2020-12-31: $881.00M2021-12-31: $967.80M2022-12-31: $885.80M2023-12-31: $783.20M2024-12-31: $701.10M2025-12-31: $368.00M$368.00M
2009-06-30 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$368.00M-47.5%2026-02-24, Balance as of period end
2024-12-31$701.10M-10.5%2026-02-24, Balance as of period end
2023-12-31$783.20M-11.6%2026-02-24, Balance as of period end
2022-12-31$885.80M-8.5%2025-02-28, Balance as of period end
2021-12-31$967.80M+9.9%2024-02-28, Balance as of period end
2020-12-31$881.00Mn/a2022-02-25, Balance as of period end
2020-06-30$918.20M-15.7%2020-08-13, Balance as of period end
2019-06-30$1.09B+12.7%2020-08-13, Balance as of period end
2018-06-30$966.10M+25.7%2019-08-13, Balance as of period end
2017-06-30$768.40M+3.9%2018-08-24, Balance as of period end
2016-06-30$739.60M+11.8%2018-08-24, Balance as of period end
2015-06-30$661.70M-8.0%2018-08-24, Balance as of period end
2014-06-30$719.00M-1.3%2016-08-10, Balance as of period end
2013-06-30$728.60M+14.6%2015-08-12, Balance as of period end
2012-06-30$635.66M+12.2%2014-08-13, Balance as of period end
2011-06-30$566.79M+1.7%2013-08-14, Balance as of period end
2010-06-30$557.58M+28.4%2012-08-15, Balance as of period end
2009-06-30$434.22Mn/a2011-08-15, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Myriad Genetics Inc (MYGN)2025-12-31$368.00M-47.5%
Neogen Corp (NEOG)2026-05-31$2.09B+1.0%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.09B+0.2%
QuidelOrtho Corp (QDEL)2025-12-28$1.92B-35.7%
Idexx Laboratories Inc (IDXX)2025-12-31$1.61B+0.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗